Highly differentiated AI-powered D-MAV discovery platform targeting drugdiscovery in the multi-billion-dollar antiviral marketsCompany to participate in Virtual Investor Closing Bell event to discuss pathforward today at 4:00 PM ET. Access the event hereCAMBRIDGE, Mass. and HOUSTON, April 9, 2026 /PRNewswire/ -- Decoy Therapeutics, Inc. (NASDAQ:DCOY) (Decoy, or the Company), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new category of antivirals engineered to work across multiple viruses, today highlighted a series of recent strategic, operational and scientific achievements that underscore accelerating momentum and a clear trajectory toward becoming a clinical

Live video webcast with Rick Pierce, Chief Executive Officer of Decoy Therapeutics, on Thursday, April 9th at 4:00 PM ETRegister for the event hereCAMBRIDGE, Mass. and HOUSTON, April 6, 2026 /PRNewswire/ -- Decoy Therapeutics, Inc. (NASDAQ:DCOY) (Decoy, or the Company), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new category of antivirals engineered to work across multiple viruses, announced that Rick Pierce, Chief Executive Officer of Decoy, will participate in a Virtual Investor Closing Bell event on Thursday, April 9, 2026, at 4:00 PM ET.  As

CAMBRIDGE, Mass. and HOUSTON, April 2, 2026 /PRNewswire/ -- Decoy Therapeutics, Inc. (NASDAQ:DCOY) (Decoy, or the Company), announces that on March 31, 2026 the Company received notification from the Nasdaq Stock Market LLC that it has regained compliance with Listing Rule 5550(a)(2), the Minimum Bid Price Requirement and is now in compliance with all other applicable continued listing requirements of The Nasdaq Capital Market. Nasdaq further notified the Company that it will be subject to a Mandatory Panel Monitor for a period of one year from March 31, 2026. If, within that on

Partnership supported by funding from Google Cloud will increase Decoy's computational peptide design bandwidth by 25-100xCAMBRIDGE, Mass. and HOUSTON, March 11, 2026 /PRNewswire/ -- Decoy Therapeutics, Inc. (NASDAQ:DCOY) (Decoy, or the Company), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new category of antivirals engineered to work across multiple viruses, today announced a collaboration with Quantori, a leading provider of digital transformation services and technology for the life sciences and healthcare industries, supported by funding from Google Cloud, to build a Google Cloud-native peptide design platform intended to dramatically increase the speed an

CAMBRIDGE, Mass., March 5, 2026 /PRNewswire/ -- Decoy Therapeutics Inc. (NASDAQ:DCOY), a preclinical-stage biopharmaceutical company that is engineering the next generation of peptide conjugate therapeutics, today announced that it will effect a 1-for-12 reverse stock split at 5:00 p.m. Eastern Time, on March 6, 2026. Beginning with the opening of trading on March 9, 2026, Decoy's common stock will trade on the Nasdaq Capital Market on a split-adjusted basis under a new CUSIP number 79400X602. The reverse stock split is intended to enable Decoy to regain compliance with the $1.0

-  Connect with the Company on Webull here CAMBRIDGE, Mass. and HOUSTON, Feb. 11, 2026 /PRNewswire/ -- Decoy Therapeutics, Inc. (NASDAQ:DCOY) (Decoy, or the Company), a preclinical biopharmaceutical that is engineering the next generation of peptide conjugate therapeutics, today announced that it is now participating on the Webull Corporate Connect Service (CCS) platform. Decoy's portal on the Webull CCS aims to provide an additional line of communication for shareholders and interested investors and enhance transparency with its growing shareholder base. Through Webull, the C

– Live video webcast on Tuesday, February 10th at 1:20 PM EST CAMBRIDGE, Mass. and HOUSTON, Feb. 5, 2026 /PRNewswire/ -- Decoy Therapeutics, Inc. (NASDAQ:DCOY) (Decoy, or the Company), a preclinical biopharmaceutical that is engineering the next generation of peptide conjugate therapeutics, today announced that it will participate in the Corporate Connect Webinar Series hosted by Webull Financial being held virtually February 10-11, 2026. As part of the presentation, Rick Pierce, Chief Executive Officer of Decoy Therapeutics, will provide a brief corporate overview, highlighti

Access the "What This Means" segment here CAMBRIDGE, Mass. and HOUSTON, Feb. 4, 2026 /PRNewswire/ -- Decoy Therapeutics, Inc. (NASDAQ:DCOY) (Decoy, or the Company), a preclinical biopharmaceutical that is engineering the next generation of peptide conjugate therapeutics, today announced that it participated in a Virtual Investor "What This Means" segment highlighting the Company's recently announced Global Access Commitment Agreement (GACA) with the Gates Foundation. The "What This Means" segment provides additional context on Decoy's plans to develop a flexible, globally acce

Decoy Therapeutics will use the platform, with funding support from the Gates Foundation, to provide widespread access to peptide-conjugate antivirals from Decoy's IMP3ACT™ platform for low- and middle-income countries. CAMBRIDGE, Mass. and HOUSTON, Jan. 13, 2026 /PRNewswire/ -- Decoy Therapeutics, Inc. (NASDAQ:DCOY) (Decoy, or the Company), a preclinical biopharmaceutical that is engineering the next generation of peptide conjugate therapeutics, announces that the development of a flexible, globally accessible manufacturing platform for peptide-conjugate antivirals is a key 'funded development' of Decoy's Global Access Commitment Agreement (GACA) with the Gates Foundation. 

Ladenburg Thalmann initiated coverage of Decoy Therapeutics with a rating of Buy and set a new price target of $2.50